US · NEO
NeoGenomics, Inc.
- Sector
- Healthcare · Medical - Diagnostics & Research
- Headquarters
- Fort Myers, FL 33912
- Website
- neogenomics.com
Price · as of 2025-12-31
$9.44
Market cap 255.21M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $23.42 | +148.09% |
| Intrinsic Value(DCF) | $3.80 | -59.75% |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $1.73 | $207.06 | $2.04 | $0.00 | $0.00 |
| 2012 | $3.80 | $1,173.36 | $4.52 | $0.98 | $0.29 |
| 2013 | $3.44 | $886.22 | $3.97 | $3.14 | $3.73 |
| 2014 | $4.61 | $70.11 | $1.31 | $5.58 | $3.78 |
| 2015 | $7.02 | $83.29 | $1.58 | $6.53 | $0.00 |
| 2016 | $7.96 | $57.67 | $213.68 | $0.56 | $0.00 |
| 2017 | $8.71 | $37.19 | $179.48 | $3.56 | $0.00 |
| 2018 | $18.76 | $56.54 | $196.97 | $7.41 | $3.27 |
| 2019 | $29.09 | $72.69 | $378.67 | $17.36 | $21.46 |
| 2020 | $49.23 | $105.23 | $155.70 | $23.21 | $3.18 |
| 2021 | $15.89 | $1,090.28 | $8.83 | $22.48 | $0.00 |
| 2022 | $16.77 | $23.34 | $0.00 | $0.00 | $0.00 |
| 2023 | $15.66 | $55.94 | $0.00 | $0.00 | $0.00 |
| 2024 | $10.10 | $260.18 | $6.46 | $0.00 | $0.00 |
| 2025 | $9.50 | $23.42 | $0.00 | $0.00 | $0.00 |
AI valuation
Our deep-learning model estimates NeoGenomics, Inc.'s (NEO) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $23.42
- Current price
- $9.44
- AI upside
- +148.09%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$3.80
-59.75% upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| NEO | NeoGenomics, Inc. | $9.44 | 255.21M | +148% | -60% | — | — | -2.25 | 0.29 | 0.33 | 318.65 | -6.35 | 9.47 | 38.85% | -9.09% | -14.85% | -12.42% | -5.70% | -7.21% | 0.56 | -17.61 | 4.26 | 3.61 | 179.17 | 3548.00% | 1011.00% | -3602.00% | -8.95% | 0.06 | -1.92% | 0.00% | 0.00% | 0.00% | -8.41 | -25.53 | 0.76 | 0.46 |
| ACRS | Aclaris Therapeutics, Inc… | $2.87 | 310.95M | +859% | -54% | — | +777% | -5.76 | 3.63 | 47.81 | -3.46 | — | 3.63 | 73.28% | -975.91% | -829.58% | -50.20% | 2416.55% | -34.10% | 0.00 | — | 5.28 | 5.28 | 0.31 | -6901.00% | -5819.00% | 13383.00% | -12.62% | -1.64 | 1494.19% | 0.00% | 0.00% | 0.00% | -2.92 | -4.72 | 28.46 | -5.14 |
| ARCT | Arcturus Therapeutics Hol… | $8.23 | 233.85M | +247% | -10% | — | +29% | -4.85 | 1.63 | 2.84 | -2.38 | -2.89 | 1.63 | 100.00% | -69.13% | -58.49% | -31.16% | -388.69% | -20.93% | 0.12 | — | 4.67 | 3.68 | 2.69 | 16786.00% | -1227.00% | 18760.00% | -15.37% | -0.91 | -245.39% | 0.00% | 0.00% | 0.00% | -1.93 | -3.05 | 1.33 | 0.78 |
| HUMA | Humacyte, Inc. | $1.12 | 159.24M | — | — | — | — | -2.46 | -6.95 | — | -2.55 | -13.86 | -6.95 | 0.00% | — | — | 760.17% | 252.76% | -111.77% | -0.31 | -12.33 | 2.40 | 2.25 | 0.21 | 1776.00% | — | 3190.00% | -27.23% | -4.92 | 220.27% | 0.00% | 0.00% | 1.48% | -2.95 | -3.39 | — | -8.31 |
| MDXH | MDxHealth S.A. | $3.40 | 174.64M | +722% | +1,396% | — | — | -2.93 | 4.89 | 0.81 | -3.90 | — | -1.18 | 61.23% | -27.45% | -42.28% | -224.25% | -91.23% | -17.26% | 4.05 | -3.24 | 1.57 | 1.44 | -0.60 | -3012.00% | 2829.00% | -2198.00% | -28.53% | -0.43 | -76.34% | 0.00% | 0.00% | 7.75% | -3.47 | -4.15 | 0.95 | -2.74 |
| QTRX | Quanterix Corporation | $6.55 | 305.96M | +237% | -22% | -45% | — | -7.37 | 0.86 | 2.10 | -0.73 | -45.26 | 0.87 | 59.89% | -38.85% | -28.45% | -11.33% | -70.92% | -9.23% | 0.11 | — | 8.66 | 7.65 | 0.44 | 1628.00% | 1180.00% | 6982.00% | -13.57% | -0.84 | -51.94% | 0.00% | 0.00% | 0.00% | -0.61 | -0.83 | 0.24 | 1.46 |
| SGMT | Sagimet Biosciences Inc. | $5.71 | 177.02M | +358% | — | — | — | -2.53 | 0.74 | — | 0.79 | — | 0.74 | 0.00% | — | — | -36.92% | -12575.98% | -35.46% | 0.00 | — | 34.30 | 33.96 | 1.66 | -523.00% | -10000.00% | 7855.00% | -36.78% | -9.53 | -9800.23% | 0.00% | 0.00% | 0.60% | 0.66 | 0.84 | — | 12.95 |
| SMTI | Sanara MedTech Inc. | $20.44 | 182.64M | +884% | +2,959% | — | — | -28.26 | 7.11 | 3.23 | -159.37 | -23.70 | -53.81 | 90.61% | -7.75% | -11.15% | -23.53% | -12.52% | -12.24% | 0.82 | -2.15 | 2.18 | 1.92 | -8.82 | 11923.00% | 3336.00% | -9279.00% | -0.09% | 0.00 | -0.47% | 0.00% | 0.00% | 0.00% | -44.15 | -1171.43 | 3.42 | 3.79 |
| TKNO | Alpha Teknova, Inc. | $2.58 | 138.11M | +974% | -63% | — | — | -7.38 | 1.85 | 3.14 | -13.45 | — | 2.24 | 33.17% | -41.90% | -42.59% | -22.83% | -21.20% | -15.52% | 0.22 | -23.91 | 4.58 | 1.40 | -0.91 | -4386.00% | 735.00% | -3170.00% | -7.25% | -1.07 | -11.53% | 0.00% | 0.00% | 13.58% | -8.04 | -14.79 | 3.37 | 0.52 |
| XGN | Exagen Inc. | $3.62 | 82.04M | +641% | +1,119% | — | — | -3.89 | 6.16 | 1.06 | -5.36 | — | 6.16 | 59.51% | -24.51% | -27.17% | -93.78% | -136.76% | -29.74% | 2.41 | -6.10 | 2.70 | 2.21 | -0.09 | -3806.00% | 589.00% | -978.00% | -23.46% | -0.98 | -138.35% | 0.00% | 0.00% | 0.00% | -4.38 | -4.33 | 1.07 | -7.36 |
About NeoGenomics, Inc.
NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States, Europe, and Asia. It operates through, Clinical Services and Pharma Services segments. The company offers testing services to hospitals, reference labs, pathologists, oncologists, clinicians, pharmaceutical firms, and researchers. It provides cytogenetics testing services to study normal and abnormal chromosomes and their relationship to diseases; fluorescence in-situ hybridization testing services that focus on detecting and locating the presence or absence of specific DNA sequences and genes on chromosomes; flow cytometry testing services to measure the characteristics of cell populations; and immunohistochemistry and digital imaging testing services to localize cellular proteins in tissue section, as well as to allow clients to visualize scanned slides, and perform quantitative analysis for various stains. The company also provides molecular testing services, which focus on the analysis of DNA and/or RNA, and the structure and function of genes at the molecular level; morphologic analysis, which is the process of analyzing cells under the microscope by a pathologist for the purpose of diagnosis; and testing services in support of its pharmaceutical clients' oncology programs covering discovery and commercialization, as well as acts as a reference laboratory supplying anatomic pathology testing services. It has a strategic alliance agreement and laboratory services agreement with Inivata Limited. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
- CEO
- Anthony Zook
- Employees
- 2.2K
- Beta
- 1.58
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($3.80 ÷ $9.44) − 1 = -59.75% (DCF, example).